← Back to Screener
Climb Bio, Inc. Common Stock (CLYM)
Price$8.82
Favorite Metrics
Price vs S&P 500 (26W)376.57%
Price vs S&P 500 (4W)15.67%
Market Capitalization$413.19M
All Metrics
Book Value / Share (Quarterly)$3.36
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.14
Price vs S&P 500 (YTD)113.61%
EPS (TTM)$-0.88
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-0.88
EPS (Annual)$-0.88
ROI (Annual)-37.30%
Cash / Share (Quarterly)$2.12
ROA (Last FY)-35.68%
EBITD / Share (TTM)$-1.00
ROE (5Y Avg)-33.67%
Cash Flow / Share (Annual)$-1.14
P/B Ratio2.57x
P/B Ratio (Quarterly)1.70x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-29.57x
ROA (TTM)-32.21%
EPS Incl Extra (Annual)$-0.88
Current Ratio (Annual)15.16x
Quick Ratio (Quarterly)14.47x
3-Month Avg Trading Volume1.08M
52-Week Price Return560.31%
Revenue / Employee (TTM)$0
52-Week High$9.25
EPS Excl Extra (Annual)$-0.88
26-Week Price Return380.56%
Quick Ratio (Annual)14.47x
13-Week Price Return84.04%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.16x
Enterprise Value$377.508
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.12
3-Month Return Std Dev92.98%
Net Income / Employee (TTM)$-2
ROE (Last FY)-37.30%
Net Interest Coverage (Annual)-13.87x
EPS Basic Excl Extra (Annual)$-0.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.88
ROI (TTM)-33.41%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)530.48%
Year-to-Date Return116.25%
5-Day Price Return7.45%
EPS Normalized (Annual)$-0.88
ROA (5Y Avg)-32.48%
Month-to-Date Return26.28%
EBITD / Share (Annual)$-1.00
ROI (5Y Avg)-33.67%
EPS Basic Excl Extra (TTM)$-0.88
P/B Ratio (Annual)1.70x
Book Value / Share (Annual)$3.36
Price vs S&P 500 (13W)83.36%
Beta-0.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-33.41%
52-Week Low$1.13
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.46
4.46
4.43
4.44
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CLYMClimb Bio, Inc. Common Stock | — | — | — | — | $8.82 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete B cells for the treatment of B-cell-mediated diseases.